Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Cash & Equivalents: 2009-2021

Historic Cash & Equivalents for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Dec 2021 value amounting to $50.7 million.

  • Avadel Pharmaceuticals' Cash & Equivalents rose 4.38% to $60.7 million in Q3 2022 from the same period last year, while for Sep 2022 it was $60.7 million, marking a year-over-year increase of 4.38%. This contributed to the annual value of $50.7 million for FY2021, which is 29.30% down from last year.
  • As of FY2021, Avadel Pharmaceuticals' Cash & Equivalents stood at $50.7 million, which was down 29.30% from $71.7 million recorded in FY2020.
  • Avadel Pharmaceuticals' Cash & Equivalents' 5-year high stood at $71.7 million during FY2020, with a 5-year trough of $9.3 million in FY2018.
  • Moreover, its 3-year median value for Cash & Equivalents was $50.7 million (2021), whereas its average is $44.1 million.
  • As far as peak fluctuations go, Avadel Pharmaceuticals' Cash & Equivalents tumbled by 57.76% in 2017, and later soared by 633.80% in 2020.
  • Over the past 5 years, Avadel Pharmaceuticals' Cash & Equivalents (Yearly) stood at $16.6 million in 2017, then crashed by 43.70% to $9.3 million in 2018, then climbed by 4.82% to $9.8 million in 2019, then surged by 633.80% to $71.7 million in 2020, then dropped by 29.30% to $50.7 million in 2021.